<DOC>
	<DOC>NCT02194985</DOC>
	<brief_summary>This is an open-label extension study intended to provide continued treatment with migalastat HCl for subjects with Fabry disease who completed treatment of a previous migalastat HCl monotherapy study. The study will assess the long-term safety and effectiveness of migalastat HCl in subjects with Fabry disease who completed migalastat HCl treatment in a previous study.</brief_summary>
	<brief_title>Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Subject had completed treatment in a previous study of migalastat HCl Age 18 years or older Male and female participant agrees to use protocol identified acceptable contraception Subject is willing to provide written informed consent and authorization for use and disclosure of Personal Health Information (PHI) Subjects last available estimated glomerular filtration rate (eGFR) in the previous study was &lt;30 mL/min/1.73m2; unless there is measured GFR available within 3 months of Baseline Visit (Visit 1), which is &gt;30 mL/min/1.73m2 Subject has undergone, or is scheduled to undergo kidney transplantation or is currently on dialysis Subject has a documented transient ischemic attack, stroke, unstable angina, or myocardial infarction within the 3 months before Visit 1 Subject has clinically significant unstable cardiac disease in the opinion of the investigator (e.g., cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or NYHA class III or IV congestive heart failure) Subject has a history of allergy or sensitivity to AT1001 (including excipients) or other iminosugars (e.g., miglustat, miglitol) Subject requires treatment with Glyset® (miglitol) or Zavesca® (miglustat) Subjects with severe or unsuitable concomitant medical condition Subjects with clinically significant abnormal laboratory value(s) and clinically significant electrocardiogram (ECG) findings at baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Fabry disease</keyword>
	<keyword>Lysosomal storage disease</keyword>
	<keyword>migalastat HCl</keyword>
	<keyword>AT1001</keyword>
</DOC>